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Neural crest cells (NCC) are a transient, embryonic
cell population characterized by unusual migratory
ability and developmental plasticity. To annotate
and characterize cis-regulatory elements utilized by
the human NCC, we coupled a hESC differentiation
model with genome-wide profiling of histone modifi-
cations and of coactivator and transcription factor
(TF) occupancy. Sequence analysis predicted major
TFs binding at epigenomically annotated hNCC
enhancers, including a master NC regulator,
TFAP2A, and nuclear receptors NR2F1 and NR2F2.
Although many TF binding events occur outside
enhancers, sites coinciding with enhancer chromatin
signatures show significantly higher sequence
constraint, nucleosomal depletion, correlation with
gene expression, and functional conservation in
NCC isolated from chicken embryos. Simultaneous
co-occupancy by TFAP2A and NR2F1/F2 is associ-
ated with permissive enhancer chromatin states,
characterized by high levels of p300 and H3K27ac.
Our results provide global insights into human NC
chromatin landscapes and a rich resource for studies
of craniofacial development and disease.
INTRODUCTION
Transcriptional enhancers are the primary determinant of cell-
type-specific gene expression (Buecker and Wysocka, 2012;
Bulger and Groudine, 2010, 2011). A central feature of enhancers
is their ability to function as integrated TF binding platforms,
recognized both by major lineage specifiers and DNA binding
effectors of signaling pathways (Buecker and Wysocka, 2012;
Mullen et al., 2011; Trompouki et al., 2011). Recent studies
showed that epigenomic profiling of chromatin features
commonly associated with enhancers, including occupancy ofCellgeneral transcriptional coactivators, hypersensitivity tonucleases,
and enrichment of certain histonemarks at flanking nucleosomes,
allows for identification of enhancers in a genome-wide, cell-type-
specific,andconservation-independentmanner (Heintzmanetal.,
2009; Rada-Iglesias et al., 2011; Visel et al., 2009).
We reasoned that hESC differentiation models combined with
epigenomic enhancer annotation and sequence analysis of the
underlying DNA can be used as an unbiased approach to identify
main TFs driving gene expression in transient cell types arising
during human development. As a proof of concept, we focus
here on the NCC, a vertebrate-specific transient embryonic cell
group that is ectodermal in origin but upon delamination from
the neural tubeacquires a remarkably broaddifferentiation poten-
tial andability tomigrate throughout thebody togive rise tocranio-
facial bones and cartilages, peripheral nervous system, pigment
cells, andcertaincardiacstructures (Gammill andBronner-Fraser,
2003; Sauka-Spengler and Bronner-Fraser, 2008). Aberrant NC
development is associatedwith a broad variety of congenitalmal-
formations, known as neurocristopathies, which, due to a critical
contribution of the NC to the head mesenchyme, often manifest
in deafness and complex craniofacial defects and include a large
variety of syndromes, as well as nonsyndromic manifestations,
such as cleft lip and palate, one of the most common congenital
defects (Birnbaum et al., 2009; Passos-Bueno et al., 2009).
Regulatory events that accompany NC formation occur at 3 to
6 weeks of human gestation and are largely inaccessible for
studies in an embryonic context (Betters et al., 2010). To over-
come this limitation we previously developed an in vitro hESC
differentiation model, which recapitulates gene expression,
migratory potential, and differentiation characteristics of NCC
(Bajpai et al., 2010). Here we use this model for genome-wide
analyses of chromatin marking patterns, gene expression, and
TF occupancy in hNCC. Through these analyses we annotate
hNCC enhancer regions and subsequently predict and confirm
that they are commonly co-occupied by the NC lineage specifier
TFAP2A and orphan nuclear receptors NR2F1/2. We further
show that these TFs synergize to bring about active chromatin
states and demonstrate the requirement for NR2F1 function in
NC gene expression, enhancer activity, and morphogenesis of
the ectomesenchyme.Stem Cell 11, 633–648, November 2, 2012 ª2012 Elsevier Inc. 633
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Epigenomic Profiling of hNCC
To obtainNCC for genomic analyses, we used an in vitro differen-
tiation model in which hESC are first induced to form neuroecto-
dermal spheres (hNEC) that subsequently give rise to migratory
cells expressing early NC markers and recapitulating neuronal,
mesenchymal, and melanocytic differentiation potential of the
NC (Bajpai et al., 2010). To examine chromatin patterns associ-
atedwithNC regulatory regionsweperformedChIP-seqanalyses
from hNCC population in which both premigratory and migratory
anterior NC fateswere represented, using antibodies recognizing
p300, H3K4me1, H3K27ac, H3K4me3, and H3K27me3 (Fig-
ure S1A available online). We identified over 4,300 genomic
elements marked by the active enhancer signature (Heintzman
et al., 2009; Rada-Iglesias et al., 2011), defined by the occupancy
of p300, with simultaneous enrichment of H3K27ac and
H3K4me1 at flanking regions and absence of H3K4me3 (listed
inDataS1). Typical of enhancers, identified elementsweregener-
ally located within 1–200 kb away from the nearest transcription
start site (TSS; Figure S1B), overlapped with FAIRE hypersensi-
tive sites (Figure S1C), and were on average more evolutionary
constrained than flanking noncoding regions (Figure S1D).
Comparisons of hNCC ChIP-seq results with the correspond-
ing data sets from hESC and hNEC (Rada-Iglesias et al., 2011)
revealed that 79% of the identified regions were marked by the
active enhancer signature in hNCC, but not hESC or hNEC (Fig-
ure 1A, example shown in Figure 1B). H3K27ac, a histone mark
tightly correlated with active enhancer states (Bonn et al., 2012;
Cotney et al., 2012; Creyghton et al., 2010; Heintzman et al.,
2009; Rada-Iglesias et al., 2011), was the most dynamic across
cell types (Figure 1C, example shown in Figure 1B), whereas
H3K4me1 was often present at the identified regions already in
hESC (Figure 1D, example shown in Figure 1B), in agreement
with its proposed role in enhancer priming (Bonn et al., 2012;
Creyghton et al., 2010; Rada-Iglesias et al., 2011). In contrast
to enhancers, considerably less cell-type-specific variation
was observed in chromatin marking patterns at proximal
promoter regions (Figure S1E). Thus, enhancer utilization is
highly dynamic even among the genetically matched and tran-
sient cell types examined in our studies.
hESC-AssociatedChromatin FeaturesAreNot Prevalent
in hNCC
Due to their extreme developmental plasticity, human NCC are
postulated to share many properties of hESC (d’Aquino et al.,
2011; Kaltschmidt et al., 2012). Among prevalent features of
hESC chromatin are so-called bivalent promoters (marked by
both H3K4me3 and H3K27me3) (Zhao et al., 2007) and poised
developmental enhancers characterized by the presence of
H3K27me3 instead of H3K27ac (Rada-Iglesias et al., 2011).
We observed these features to be much less abundant in
hNCC, whereas the number of enhancers and promoters
marked by active signatures is comparable between the two
cell types (Figures 1E and 1F). This result is not an artifact of inef-
fective H3K27me3 ChIP-seq in hNCC, as the number of
H3K27me3-only marked promoters is higher in hNCC than in
hESC. In addition, we cannot exclude the possibility that
a portion of the observed hNCC bivalent promoters and poised634 Cell Stem Cell 11, 633–648, November 2, 2012 ª2012 Elsevier Inenhancers arises from heterogeneity in the hNCC population,
rather than true bivalency. Regardless, our results suggest that
hNCC did not broadly coopt typical hESC chromatin features;
however, it remains a possibility that rare cells within our popu-
lation do exhibit hESC-like properties.
Functional Annotation of hNCC Enhancers Reveals
Association with Craniofacial Development and Disease
To test whether the presence of the identified putative enhancer
regions positively correlates with expression of nearby genes,
we performed polyA transcriptome analysis of hNCC by RNA-
seq and validated the results by RT-qPCR analysis of selected
transcripts (Data S2, Figure S1F). Transcriptome profiling
confirmed our earlier observations that hNCC express well-char-
acterized NC markers (e.g., TWIST1, SNAI1, SNAI2, SOX9,
SOX10, SOX11, FOXD3, NGFR [p75], and TFAP2A) and showed
that these cells are HOX-negative and DLX1/2-positive, a gene
expression pattern consistent with the dorsal-anterior cranial
NCC, which preferentially differentiate into ectomesenchymal
derivatives and give rise to the majority of craniofacial bones
and cartilages (Minoux and Rijli, 2010). We next examined
expression of transcripts arising from the TSS closest to hNCC
enhancers and observed a strong positive correlation between
identified regions and genes highly expressed and upregulated
in hNCC (Figure 1G).
Functional annotation of hNCC enhancers using GREAT
(McLean et al., 2010) showed association with genes expressed
in neurectoderm, branchial arches, and head mesenchyme
consistent with the dorsal-anterior premigratory and migratory
NC identity of the analyzed cell population (Figure 2A, top panel).
Strikingly, when we considered mouse phenotypes associated
with deletion of genes linked to the identified enhancers, the
most enriched categories included abnormalities of cranial
bones, neural tube defects, and malformations of NC-derived
facial structures, such as the mandible, maxilla, and palate (Fig-
ure 2A, middle panel). Moreover, when associations with human
malformations were considered, enriched categories included
cleft lip/palate, abnormalities of palpebral fissures and ear struc-
tures, and other craniofacial anomalies, all consistent with
defects of cranialNC-derivedheadmesenchyme (Passos-Bueno
et al., 2009), as well as open (patent) ductus arteriosus, a special-
ized heart blood vessel derived largely from the cardiac NC (Ivey
et al., 2008) (Figure 2A, bottompanel). Associationwith handmal-
formations was also detected, which is not unexpected, as limb
anomalies are commonly associated with neurocristopathies
(Tucker et al., 1999). A large number of genes previously impli-
cated in NCdevelopment, Wnt signaling, cell migration, andmal-
formations including cleft lip/palate, frontonasal dysplasia, and
patent ductus arteriosus have at least one hNCC enhancer
located in relative proximity (select functional categories and cor-
responding genes are shown in Table S1). Taken together, our
data strongly suggest that the identified elements represent
bona fide active enhancers relevant for NC gene expression,
human craniofacial development, and neurocristopathogenesis.
Conservation of Enhancer H3K27ac Patterns in Chicken
Embryo NCC
Regulatory regions commonly show lower evolutionary
constraint than coding sequences (Bulger and Groudine, 2010,c.
Figure 1. Epigenomic Mapping Uncovers hNCC Enhancer Elements
(A) Cell type specificity of hNCC active enhancer regions.
(B) p300, H3K27ac, H3K4me1, and H3K4me3 enrichment profiles in hESC, hNEC, and hNCC at a representative hNCC enhancer (e.g.,WNT9A). The peak height
corresponds to normalized fold-enrichments calculated by QuEST.
(C and D) Average hNCC H3K27ac (C) and H3K4me1 (D) ChIP-seq signal profiles around the central position of p300 peaks at unique hNCC active enhancers.
(E) Number of H3K4me3-only, bivalent (i.e., enriched in both H3K4me3 and H3K27me3), and H3K27me3-only promoters in hESC and hNCC.
(F) Number of active and poised enhancers in hESC and hNCC.
(G) Gene expression, measured as RPKMs, calculated for all human ENSEMBL genes and for those closest (within 100 Kb) to hNCC active enhancers. Expression
levels are presented as boxplots.
p values were calculated using paired Wilcoxon tests. See also Figure S1.
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Figure 2. Functional Annotation and Sequence Analysis of Active hNCC Enhancers
(A) Annotation of hNCC active enhancers. Mouse Genome Informatics (MGI) Expression Detected (red) ontology contains information on tissue and
developmental stage-specific expression in mouse; Mouse Phenotypes (blue) ontology contains data on mouse genotype-phenotype associations; Human
Malformations (purple) ontology contains data on human genotype–phenotype associations. The x axis values correspond to Binomial raw (uncorrected)
p values.
(B) Dorsal anterior neural folds from st8 chicken embryos were excised (red line) and cultured ex vivo for 72 hr, resulting in emigration of NCC estimated to
correspond to chicken st11–14 cranial NCC.
(C) Chicken st20 NCCwere isolated in vivo from frontonasal prominences (FNP). FNPs were incubated with dispase in order to remove the surface ectoderm and
forebrain neuroectoderm, which resulted in FNPs solely comprised of NCC.
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responding conserved sequences can be identified in the
chicken genome. Therefore, to further support biological rele-
vance of the identified human enhancers, we examined conser-
vation of H3K27ac, a chromatin mark closely associated with
enhancer activity, at these corresponding regions in chicken
NCC. To obtain chicken NCC we dissected the dorsal anterior
neural folds from embryos prior to the onset of NC migration
(st8) and cultured them ex vivo for 72 hr (approximately st11–
14), allowing NCC to emigrate out (Figure 2B). In parallel, we
dissected the frontonasal prominences of st20 embryos and
separated NCC away from the epithelium (Figure 2C) (Brugmann
et al., 2010). We chose the frontonasal prominence over other
facial prominences because it is solely comprised of NC mesen-
chyme. These early and late chicken NCC populations were then
analyzed by H3K27ac ChIP-seq. Average H3K27ac enrichment
profiles were generated over chicken genomic regions corre-
sponding to hNCC enhancers or, to control for specificity, those
corresponding to hESC enhancers. Remarkably, regions corre-
sponding to hNCC enhancers showed high enrichment of
H3K27ac in chicken NCC (both early and late) with a character-
istic central dip in enrichment profile, indicative of the presence
of nucleosomal depletion/hypermobility regions typical of
enhancers (Figures 2D and 2E). As exemplified by the conserved
enhancer acetylation patterns at select NC gene loci, corre-
sponding chicken enhancers were acetylated either in both
chicken NCC populations or preferentially in one population
(e.g., compare PLXND1 and ETS1 loci with MYCN locus) (Fig-
ure S2A). Taken together, these results validate biological rele-
vance of our analysis and uncover conservation of H3K27ac
patterns at NCC enhancers between species.
To further substantiate functional conservation of identified
regulatory regions, we selected three human elements and
tested their activity in vivo in the zebrafish transgenic enhancer
reporter assay (Figure S2B). The selected enhancers (named
A, B, and C) were proximal to, respectively, WNT1, CCND1,
and BMP7 genes and corresponded to uncharacterized
genomic sequences, with the exception of the WNT1 proximal
enhancer, which falls within a broader region homologous to
that commonly used as WNT1 NC-specific driver in mouse
conditional knockout experiments (Echelard et al., 1994). Impor-
tantly, all three tested enhancers showed GFP expression in
cranial NCC migrating to anterior branchial arches, as demon-
strated by colocalization with Sox10 reporter-labeled cells (in
red) (Figure S2C). In addition, enhancers proximal to WNT1
and BMP7 showed activity in the dorsal neural tube, where de-
laminating NCC could be observed (Figure S2C).
WidespreadAssociation of hNCCEnhancerswith theNC
Master Regulator TFAP2A
We hypothesized that interrogation of DNA sequence motifs
most recurrent at hNCC enhancer regions will reveal identity of
major TFs driving NC gene expression. The most highly overrep-
resented motif corresponds to the recognition sequence for(D and E) Average ChIP-seq H3K27ac profiles from chicken NCC at st11-14 (D) o
the chicken genome.
(F) Select overrepresented DNA sequence motifs enriched at hNCC active enhan
Statistical significance (p value) of the motifs over-representation is shown. See
CellTFAP2A (a.k.a. AP2a), a TF implicated in NC induction, specifi-
cation, and differentiation (Figure 2F) (de Croze´ et al., 2011).
TFAP2A deletion in mice results in severe dysmorphogenesis
of the face, skull, sensory organs, and cranial ganglia (Schorle
et al., 1996), whereas in humans mutations in TFAP2A cause
autosomal-dominant branchiooculofacial syndrome (BOFS),
characterized by malformations of craniofacial structures of
NC origin (Milunsky et al., 2008).
Despite the critical role of TFAP2A, its genomic location in the
context of NC remains unknown. To test whether TFAP2A is
broadly associated with hNCC enhancers we performed
TFAP2A ChIP-seq analysis, which identified 16,851 high-confi-
dence binding sites, of which 12,305 (73%) were promoter distal
(Figures 3A–3B). As expected, the TFAP2A consensus binding
sequence was the most overrepresented motif among bound
regions, even in a de novo analysis (Figure 3C), with 90% of
bound regions containing at least one strong TFAP2A consensus
binding sequence. Importantly, 30% of all hNCC enhancer
regions were bound by TFAP2A (a representative locus is shown
in Figure 3A), indicating extensive occupancy of TFAP2A at
hNCC enhancers. To further validate our data we performed
ChIP-qPCR analyses from cells corresponding to two develop-
mental time points: (1) neuroectodermal rosettes (hNEC) just
prior to NCmigration and (2) hNCC after migration from rosettes.
Low or no TFAP2A binding was detected at any of the interro-
gated regions in hNEC, but significant TFAP2A enrichment was
observed at enhancers bound by TFAP2A according to ChIP-
seq in hNCC (Figure 3D).
Chromatin Signatures Facilitate Identification
of Relevant TFAP2A Binding Sites
Although nearly one-third of hNCC enhancer regions are occu-
pied by TFAP2A, surprisingly, only 10% of distal TFAP2A sites
coincide with the presence of the active enhancer signature,
with an additional 30% of sites occurring within regions marked
by a ‘‘partial’’ signature (that is, only p300 or only enhancer-asso-
ciated histone modifications) (Figure 3E). To examine whether
the presence or absence of enhancer signatures at TFAP2A sites
reflects biologically meaningful differences, we compared
genomic properties of TFAP2A sites with or without enhancer
chromatin signatures. On average, TFAP2A enrichment levels
at regions overlapping active signatures were less than 1.5-
fold higher than over unmarked regions (Figure 3F). Indeed,
robust TFAP2A binding at sites occurring within unmarked chro-
matinwas evident upon examination of individual loci (for a repre-
sentative example, see Figure 3B), indicating that unmarked
sites do not simply represent weak affinity associations. Strik-
ingly, both nucleosomal depletion/hypermobility measured by
FAIRE, as well as DNA sequence conservation, were substan-
tially stronger at TFAP2A sites overlapping active signatures
than at those unmarked, with sites overlapping ‘‘partial’’ signa-
tures falling in between (Figures 3G and 3H). Although, on
average, TFAP2A-bound regions overlapping active signatures
were more evolutionary constrained in sequence, we could stillr st20 (E) generated around central positions of hNCC enhancers conserved in
cers.
also Figure S2.
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Figure 3. Occupancy of TFAP2A at Active hNCC Enhancers
(A and B) ChIP-seq enrichment profiles in hNCC for two representative TFAP2A bound loci, either (A) overlapping an active hNCC enhancer or (B) occurring within
unmarked chromatin. The peak height corresponds to normalized fold-enrichments calculated by QuEST.
(C) Top overrepresentedmotifs enriched at distal TFAP2A-bound regions based onmatches to known transcription factors (left) or through de novomotif analysis
(right).
(D) TFAP2A ChIP-qPCR analyses of select distal TFAP2A sites identified by ChIP-seq performed from chromatin isolated from hNCC or neurectodermal spheres
(hNEC), just prior to attachment and emigration of hNCC. Error bars represent standard deviation (SD) from three technical replicates.
(E) Percentage of distal TFAP2A sites that overlapped active hNCC enhancers (red), regions with a partial active enhancer signature (blue), or unmarked chromatin
(black).
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genome. Nonetheless, when we compared H3K27ac patterns
over these corresponding regions in chicken NCC, we observed
that conserved TFAP2A sites that coincided with active signa-
tures in hNCC were also enriched for H2K27ac in chicken
NCC, while conserved unmarked TFAP2A sites showed no
such enrichment (Figure 3I, Figure S3), supporting functional
conservation of TFAP2A binding events.
Importantly, TFAP2A sites overlapping active or partial
enhancer signatures were linked to genes highly expressed
and upregulated in hNCC, but unmarked TFAP2A sites showed
no correlation with elevated expression in any of the examined
cell types (Figure 3J). Similarly, functional annotation of TFAP2A
sites overlapping active enhancers linked them to NC and
craniofacial genes, whereas unmarked TFAP2A sites lacked
clear association with NC or other tissues (data not shown).
Taken together, these results suggest that chromatin signatures
can facilitate identification of TFAP2A sites relevant for NC gene
expression (and, perhaps more generally, identification of
productively engaged TF sites, see Discussion) and indicate
that TFAP2A binding is not sufficient for the assembly of the
productive enhanceosome complexes.
Sequence Analysis of hNCC Enhancers Detects
Recognition Motifs of Major NC TFs and Signaling
Effectors
We hypothesized that to activate NC gene expression, TFAP2A
cooperates with additional sequence-specific TFs binding at
hNCC enhancer elements. We reasoned that such factors
should be well expressed in NC and their recognition motifs
overrepresented at hNCC enhancers. We therefore re-examined
enriched hNCC enhancer sequence motifs, which, in addition to
the TFAP2Amotif, included those for zinc finger protein ZIC1; the
insulator binding protein CTCF; two highly related orphan
nuclear receptors, NR2F1 and NR2F2 (a.k.a. COUP TF1 and
COUP TF2); ETS-domain TFs; and Helix-loop-Helix TFs recog-
nizing the E-box (Figure 2F). Also detectable, albeit with lower
statistical significance, were recognition motifs for the WNT-
signaling effector TCF3, the BMP-signaling effector SMAD4,
and the SOXE family TFs, such as SOX10 (Figure 2F). These
results are in close agreement with genetic and embryological
NC studies in model organisms, which implicated Zic1 (Sato
et al., 2005), Sox10 (Honore´ et al., 2003), Ets-1 (The´veneau
et al., 2007), and E-box binding proteins c-Myc, Twist, and
Snail1/2 as critical regulators of NC development (Aybar et al.,
2003; Bellmeyer et al., 2003; Soo et al., 2002; Taneyhill et al.,
2007). Moreover, Wnt and Bmp signaling plays a major role in
NC formation (Garcı´a-Castro et al., 2002; Liem et al., 1995),
and it is not unexpected that effectors of these pathways, such
as TCF3 and SMAD4, converge on hNCC enhancers. Thus, our(F–H) Average TFAP2AChIP-seq (F), FAIRE-seq (G), and vertebrate Phastcons (H)
active hNCC enhancers (red), displaying a partial active enhancer signature (blue
(I) Average chicken st20 NCC H3K27ac ChIP-seq signal profiles around the cen
overlapping active hNCC enhancers (red) or occurring within unmarked chromat
(J) Gene expression, measured as RPKMs, was calculated for all human ENSEMB
overlapping active hNCC enhancers (red), displaying a partial active enhancer sig
are presented as boxplots.
p values were calculated using Wilcoxon tests. See also Figures S3 and S9.
Cellanalysis identified a majority of the known NC TFs and signaling
effectors, with a notable exception of FoxD3 (Teng et al., 2008).
However, FoxD3 has been shown to predominantly act as
a repressor (Pohl and Kno¨chel, 2001), and it is conceivable that
it binds genomic sites distinct from active enhancer regions.
Regardless, our data underscore the validity of the epigenomic
approach and suggest that humans utilize the same major NC
TFs as other vertebrates.
Nuclear Receptor NR2F1 Regulates NC Gene
Expression
Interestingly, two of the highly enriched motifs represent recog-
nition sites for TFs previously not implicated in NC development,
CTCF and NR2F1/2. In contrast to the ubiquitously expressed
CTCF, expression ofNR2F1 andNR2F2mRNAwas dramatically
upregulated during hESC differentiation to hNCC (over 40,000-
fold and 4,000-fold, respectively; Figure 4A). Indeed, NR2F1
and NR2F2 were the most highly expressed and most highly up-
regulated in hNCC of all interrogated nuclear receptors (Fig-
ure 4B). This upregulation was accompanied by extensive chro-
matin remodeling at the NR2F1 and NR2F2 gene loci
(Figure S4A), as has been reported for other master develop-
mental regulators undergoing activation (Cotney et al., 2012),
and by the induction of respective protein products (Figure 4C).
We reasoned that NR2F1 and NR2F2 represent candidates for
new NC TFs that may synergize with TFAP2A at hNCC
enhancers. Consistently with such possibility, NR2F1/2 recogni-
tionmotif is overrepresented not only at hNCC enhancer regions,
but also at TFAP2A distal sites (Figure S4B), with a strong pref-
erence for those overlapping enhancer signatures.
To establish whether NR2F1 function is important for tran-
scription of NC genes we induced expression of aNR2F1-target-
ing shRNA during differentiation of hESC to hNCC. In several
independent experiments, we observed approximately a 50%–
70% reduction in NR2F1 mRNA compared to control cells ex-
pressing a scrambled shRNA (Figure 4D, Figure S4C). Impor-
tantly, while genes associated with neural induction (e.g., NES,
HES1) or housekeeping genes (e.g., TAF11, CKB) were only
modestly affected, multiple genes involved in NC and/or cranio-
facial development (e.g., SNAI1, DLX1, ALX3, MYCN, SOX9,
CDON, RARA, ROR2), as well as TFAP2A and NR2F2, were
significantly downregulated upon NR2F1 knockdown (Figure 4D,
Figure S4C), suggesting a major role for NR2F1 in NC gene
regulation.
NR2F1 Downregulation Perturbs Craniofacial
Development in Xenopus
Due to the fundamental contribution of the NC into the head
skeleton and face, craniofacial defects are a hallmark of human
neurocristopathies and perturbations of NC regulators in animalsignal profiles around the central position of distal TFAP2A regions overlapping
), or occurring within unmarked chromatin (black).
tral position of TFAP2A bound regions conserved in the chicken genome and
in (black).
L genes and for those closest (within 100 Kb) to distal TFAP2A bound regions
nature (blue) or occurring within unmarked chromatin (black). Expression levels
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Figure 4. NR2F1/2 Are Induced in hNCC and Regulate Expression of NC Genes In Vitro and Craniofacial Development In Vivo
(A) Expression of NR2F1 and NR2F2 was measured in hESC, hNEC, and hNCC using RT-qPCR. Expression normalized to that of the housekeeping gene EEF2
and presented relative to hESC in a logarithmic scale is shown. Error bars represent SD from three technical replicates.
(B) Expression of select nuclear receptors, including NR2F1 and NR2F2, as measured by RNA-seq (RPKMs).
(C) Immunoblot analyses of TBP, OCT4, NR2F2, and NR2F1 in hESC and hNCC.
(D) Expression of indicated genes was measured by RT-qPCR in hNCC expressing shRNA against NR2F1 (green). For all genes, expression is normalized to that
of the housekeeping gene EEF2 and presented relative to hNCC expressing control-scrambled shRNA (gray). Error bars represent SD from three technical
replicates.
(E) Craniofacial defects in tadpoles raised from two-cell-stage embryos injected into both blastomeres with nr2f1 MO, control-injected, or co-injected with nr2f1
MO and human NR2F1mRNA. Embryos were stained with alcian blue beyond stage 40–45 to visualize craniofacial cartilages. For each set of injected embryos,
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we turned to the Xenopus laevis embryo model to examine the
functional consequences of NR2F1/2 depletion for craniofacial
morphogenesis. RNA in situ hybridizations for Xenopus nr2f1
and nr2f2 demonstrated that both genes are expressed in similar
structures during Xenopus laevis embryogenesis, including
brain, eyeprimordia, heart field, and early somites, in accordance
with earlier reports (FiguresS5A andS5B).With respect toNC, no
expression was detected at the neural plate border/premigratory
crest at the early neurula stage, but by the late neurula stage nr2f2
expressionwas apparent in the streams ofmigrating cranial NCC
(Figures S5A and S5B; see arrows; of note, this was less evident
for nr2f1, but the nr2f2 probe generally gave stronger signal). At
the tailbud stage strong expression of both nr2f1 and nr2f2 was
observed in the first, second and third branchial arch (Figures
S5A and S5B), in agreement with a potential role of these recep-
tors in the cranial NCC and ectomesenchyme.
To examine the functional consequences of nr2f1 knockdown
on NC-derived cranial cartilage, both blastomeres of two-cell-
stage embryos were injected with morpholino oligonucleotide
(MO) targeting translation of nr2f1 mRNA (Figure 4E). Resultant
morphants exhibited severe and penetrant craniofacial dysmor-
phisms and defects of NC-derived cartilages (p = 2.9 3 E-13),
which were absent in control embryos and partially rescued
(p = 4.1 3 E-6) in embryos coinjected with MO and mRNA of
the corresponding human factor (Figures 4E and 4F). We also
performed experiments with spatially restricted knockdowns,
in which nr2f1 MO was coinjected with a fluorescent lineage
tracer into a single dorsal-animal (DA) blastomere of eight-cell-
stage embryos. Such targeted injection restricts the MO to the
neural tube and DA structures on the injected side of the embryo
(overlapping with the majority of the cranial NC and its deriva-
tives), while leaving the uninjected side as a control for relative
comparisons (Figure S5C). Phenotypic analysis of the DA blasto-
mere-injected nr2f1 morphants revealed craniofacial dysmor-
phisms and cranial cartilage defects on the injected side; these
malformations were rescued by coinjection of the corresponding
humanmRNA (Figures S5D and S5E). In sum, our results demon-
strate that nr2f1 downregulation is associated with ectomesen-
chyme defects typical of perturbations in NC regulators.
Certainly, nr2f1 morphants show additional abnormalities
consistent with reported roles of nr2f1 in other tissues. In addi-
tion, we cannot exclude the possibility of non-cell-autonomous
contribution to observed ectomesenchyme defects. Nonethe-
less, considering in vivo phenotype and autonomous require-
ment for NR2F1 in NC gene expression in vitro, our cumulative
observations are in agreement with the direct role of NR2F1 in
cranial NC regulation.
NR2F1 and NR2F2 Occupy Enhancers Located
in Proximity of Critical NC Genes
To investigate NR2F1 and NR2F2 genomic occupancy in hNCC
we performed ChIP-seq analyses, which identified 2,400 anddorsal and lateral views of the head are shown, as well as dissected ventral (i.e.,
quadrate; Et, ethmoid; So, subocular).
(F) Penetrance of craniofacial dysmorphisms in analyzed tadpoles.
p values were calculated using hypergeometric tests and represent the statistical
mRNA rescues (versus nr2f1 MO), respectively. See also Figures S4 and S5.
Cell2,042 high-confidence sites, respectively, with a pronounced
overlap in binding patterns of the two factors, consistently with
similar DNA binding specificity and NR2F1-NR2F2 heterodimeri-
zation (Cooney et al., 1992) (Figure 5A). NR2F1 sites identified as
NR2F2-negative with our stringent calling cutoffs had nonethe-
less subthreshold NR2F2 enrichment and vice versa (Figures
S6A and S6B). Furthermore, average enrichment profiles at
NR2F1/2 co-occupied, NR2F1-only, or NR2F2-only occupied
sites revealed binding of both nuclear receptors in all three cate-
gories (Figures S6C–S6E), suggesting that our peak calling cut-
offs underestimated the true degree of NR2F1 and NR2F2
binding overlap. We therefore considered a combined NR2F1/2
binding data set (comprised of 3,262 genomic regions, Figure 5A,
Data S3) for further analyses. ChIP-qPCR from an independently
derived hNEC and hNCC samples confirmed hNCC-specific
association of NR2F1 and NR2F2 with regions identified by
ChIP-seq, as well as enrichment of NR2F2 at NR2F1-only sites
(e.g., FOXC1, PAX7) and of NR2F1 at NR2F2-only sites (e.g.,
PGS1, APCDD1) (Figures 5B and 5C).
A strong overrepresentation of the NR2F1/2 and TFAP2A
motifs was detected at NR2F1/2 bound sites (Figure 5D). More-
over, the majority of identified NR2F1/2 regions coincided with
active (28%) or partial (33%) enhancer chromatin signatures
(Figure 5E). As observed for TFAP2A, NR2F1/2 sites overlapping
active signatures displayed higher nucleosomal depletion and
sequence conservation than unmarked sites (Figures S6F and
S6G) and showed much stronger association with genes upre-
gulated in hNCC (Figure 5F), further generalizing the usefulness
of combining TF binding data with epigenomic profiles for iden-
tification of relevant TF sites. Inspection of individual loci re-
vealed NR2F1/2 binding in proximity of NC genes downregu-
lated upon knockdown of NR2F1, including SNAI1, TFAP2A,
ALX3, CDON, MYCN, RARA, ROR2, DLX1, SOX9, and NR2F2
(examples shown in Figures 5G and 5H).
NR2F1/2 Binding Sites Are Required for Activity
of Select hNCC Enhancers
Association of NR2F1 binding sites with active enhancer regions
located in proximity of genes induced in the NC, as well as down-
regulation of NC genes upon NR2F1 knockdown, suggest that in
the context of hNCC NR2F1 acts primarily as an activator.
However, in other contexts NR2F1/2 were shown to function
as repressors (Lin et al., 2011; Tsai and Tsai, 1997). To address
whether the presence of the NR2F1/2 DNA recognition
sequence contributes to the enhancer activity, we selected
two NR2F1/2-bound hNCC enhancers, each containing a single
NR2F1/2 motif. These regions were proximal to, respectively,
BMP7 (Enhancer 1) and CDON (Enhancer 2) genes, whose
expression was induced during differentiation of hESC to
hNCC and downregulated upon NR2F1 knockdown in hNCC
(Figure 4D). hESC were transduced with GFP reporters contain-
ing either wild-type (WT) enhancer or a mutant version with dele-
tion of the NR2F1/2 binding motif (DNR2F1/2) (Figure 6A). InC, ceratohyal; Bh, basihyal; B, branchial) and dorsal cartilages (M, Meckel; Q,
significance of the nr2f1 MO induced defects (versus control) and of the NR2F1
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Figure 5. Genome-wide Analysis of NR2F1/2 Occupancy in hNCC
(A) Overlap between NR2F1 (brown) and NR2F2 (red) binding sites in hNCC.
(B and C) Chromatin isolated from hNCC and neurectodermal spheres (hNEC), just prior to attachment and emigration of hNCC, was used for NR2F1 (B) and
NR2F2 (C) ChIP-qPCRs. Error bars represent SD from three technical replicates.
(D) Top overrepresentedmotifs enriched at distal NR2F1/2-bound regions based on either de novomotif analysis (top, whichmatches NR2F1/2 motif) or matches
to known transcription factors (bottom).
(E) Percentage of distal NR2F1/2 sites that overlapped active hNCC enhancers (red), regions with a partial active enhancer signature (blue), or regions that
occurred within unmarked chromatin (black).
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Figure 6. In Vitro Reporter Assays Demon-
strate the Importance of NR2F1/2 Sites for
hNCC Enhancer Activity
(A) Schematic representation of in vitro reporter
assays. Select enhancers with intact (WT) or
deleted (D) NR2F1/2 sites were cloned in front of
a minimal promoter driving GFP expression. The
resulting lentiviral vectors were used to infect
hESC and GFP expression was subsequently fol-
lowed during hNCC differentiation.
(B and C) Bright-field and GFP images for two
select enhancers in either hESC (left panels) or
hNCC (right panels). In both cases, representative
images obtained with intact (WT) enhancers or
enhancers with deleted (D) NR2F1/2 sites are
shown. NS, neurosphere; DC, delaminating neural
crest cells; MC, migratory NCC.
See also Figure S7.
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WT reporters were induced during differentiation to hNCC, with
the first reporter being active most strongly in the delaminating
hNCC and attached rosettes, with some activity in migratory
hNCC (Figure 6B), and the second reporter showing activity
specific to a fraction of the migratory hNCC (Figure 6C). In
support of the NR2F1/2 activating role, for both reporters dele-
tion of the NR2F1/2 binding site strongly diminished enhancer
activity (Figures 6B and 6C, quantified in Figure S7).
Simultaneous Binding and Cooperation of NR2F1/2 and
TFAP2A at hNCC Enhancers
Next we proceeded to examine a potential interplay between
NR2F1/2 and TFAP2A. Comparisons of binding data sets
showed that a substantial fraction (38%) of NR2F1/2 distal sites
was also bound by TFAP2A, with co-occupied sites character-
ized by a very strong association with cranial NC-derived struc-
tures, skull formation, and craniofacial anomalies, but, in
contrast to all hNCC, not with neural or neural tube ontologies
(Figure S8A, compared with Figure 2A). Many TFAP2A and(F) Expression levels, measured as RPKMs, were calculated for all human ENSEMBL genes and for those clos
overlapping active hNCC enhancers (red), displaying a partial active enhancer signature (blue), or occurring w
are presented as boxplots. p values calculated using Wilcoxon tests.
(G and H) ChIP-seq enrichment profiles in hNCC for two representative NR2F1/2-bound loci (proximal to
enhancers.
See also Figure S6.
Cell Stem Cell 11, 633–648,NR2F1/2 co-occupied sites are located
in proximity of genes encoding NC tran-
scriptional regulators (e.g., SOX9,
TFAP2A, SNAI1), signaling mediators
involved in NC formation and differentia-
tion (e.g., BMP7, BMP4, NOTCH1,
EFNB1), and genes associated with
craniofacial anomalies in humans (e.g.,
ALX3, CHD7, TCOF1) (genomic coordi-
nates of all co-occupied distal regions
are listed in Data S4, along with names
of proximal genes). To directly demon-
strate that NR2F1/2 and TFAP2A co-bound hNCC enhancers are indeed simultaneously occupied
by these TFs, we performed sequential ChIP assays, which
showed enrichment of NR2F1-NR2F2, NR2F1-TFAP2A, and
NR2F1-p300 signals over NR2F1-IgG signal at hNCC enhancers,
but not at control regions (Figure 7A). Furthermore, coimmuno-
precipitation assays revealed association of the four proteins
(i.e., NR2F1, NR2F2, TFAP2A, and p300) in hNCC nuclear
extracts (Figures 7B and 7C). Time-course ChIP-qPCR experi-
ments showed that NR2F1 and TFAP2A bind hNCC enhancer
regions at similar time points during differentiation, coinciding
with the onset of hNCC migration and gain of H3K27ac (Figures
S8B–S8E).
Synergy between TFAP2A and NR2F1/2 is suggested by the
tendency of the co-occupied sites to occur within regions
marked by the active chromatin signatures (Figure 7D). Nonethe-
less, direct regulation of TFAP2A and NR2F2 expression by
NR2F1 makes dissecting the contribution of each factor to the
enhanceosome complex formation difficult in knockdown exper-
iments. Instead, we examined whether genomic elements bound
by both TFs, compared to regions bound by a single TF, displayest (within 100 Kb) to distal NR2F1/2 bound regions
ithin unmarked chromatin (black). Expression levels
ALX3 (G) and SNAI1 (H) overlapping active hNCC
November 2, 2012 ª2012 Elsevier Inc. 643
Figure 7. TFAP2A and NR2F1/2 Simultaneously Bind and Cooperate at hNCC Enhancers
(A) Sequential ChIPs were performed using NR2F1 as the first antibody, followed by NR2F2 (blue), TFAP2A (red), or p300 (green) antibodies. Resulting material
was analyzed by qPCR analyses of select hNCC enhancers. y axis shows fold enrichment over a NR2F1-IgG sequential ChIP. Error bars represent SD from three
technical replicates.
(B and C) NR2F1 (B) and NR2F2 (C) immunoblot analyses of NR2F1, NR2F2, TFAP2A, p300, or IgG immunoprecipitates from hNCC nuclear extracts.
(D) Percentage of distal sites bound only by TFAP2A (purple), bound only byNR2F1/2 (red), or coboundby both TFAP2AandNR2F1/2 (green), which overlap active
hNCC enhancers (Active), regions with a partial active enhancer signature (Partial) or regions occurring within unmarked chromatin (Unmarked). p values were
calculated using hypergeometric tests, based on comparisons with all TFAP2A and NR2F1/2 combined bound regions (n = 13990). NS = nonsignificant (p > 0.05).
(E and F) Average p300 (E) and H3K27ac (F) ChIP-seq signal profiles generated around the central position of distal regions bound only by TFAP2A (purple), bound
only by NR2F1/2 (red), or cobound by both TFAP2A and NR2F1/2 (green).
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pronounced H3K27ac levels. On average, cobound regions had
modestly elevated levels of TF binding, substantially increased
levels of p300, and much higher and broader enrichment of
H3K27ac (Figures S8F–S8H, Figures 7E and 7F). These results
argue for a synergistic function of TFAP2A and NR2F1/2 in es-
tablishing permissive chromatin states at hNCC enhancers.
DISCUSSION
Our study illustrates how coupling of hESC differentiation
models with epigenomic profiling holds predictive power in the
analysis of major TFs driving gene expression in developmentally
transient cell states. Below we discuss broad implications of our
work for studies of human development and disease and for
understanding general mechanisms governing cell-type-specific
transcriptional regulation during embryogenesis.
Integration of Lineage and Signaling Information at NC
Enhancers
Our results suggest that sequence information encoded by
hNCC enhancers is simultaneously read by a master lineage
specifier, TFAP2A, and by nuclear receptors, leading in turn to
the establishment of the transcriptionally permissive enhancer
chromatin states (Figure 7G). Nuclear receptors are effectors
of ligand-dependent signaling, and although the physiological
ligand of NR2F1/2 has not been identified, a structural study
convincingly argues that these TFs indeed function as ligand-
induced activators (Kruse et al., 2008). Beyond providing a direct
link between the signaling environment and the transcriptional
machinery controlling NC function, the importance of identifying
such ligand in the future is underscored by observations that
human craniofacial development is particularly sensitive to
environmental changes resulting from fetal exposure (Lammer
et al., 1985).
Whereas our work identified TFAP2A and NR2F1/2 as major
hNCC enhancer binding proteins, analysis of motifs overrepre-
sented at hNCC enhancers suggests that other TFs, such as
ETS, E-box, and SoxE factors, aswell as transcriptional effectors
of signaling pathways, includingWnt and BMP, also assemble at
hNCC enhancers (Betancur et al., 2010; Sauka-Spengler and
Bronner-Fraser, 2008). Future genome-wide studies will be
needed to clarify the binding pattern overlap and spatiotemporal
relationships among these factors. Nonetheless, our results
suggest that, as has been reported in other systems (Mullen
et al., 2011; Trompouki et al., 2011), synergistic function of
lineage specifiers and signaling effectors converges at NC
enhancer elements.
Chromatin Signatures Facilitate Identification of TF
Sites Engaged in Productive Enhanceosomes
TFAP2A and NR2F1/2 binding sites that coincide with the pres-
ence of active signatures display much higher levels of nucleo-(G) Proposed model of hNCC enhancer activation, whereby a master lineage
simultaneously bind enhancer sequences and synergistically lead to the estab
activation. Additional TFs (depicted as ‘‘TFs?’’), including NC specifiers and effect
the combinatorial recruitment of productive enhanceosomes.
See also Figure S8.
Cellsomal depletion/hypermobility, association with gene expres-
sion, and functional conservation than TF sites not overlapping
with enhancer signatures. A similar correlation may hold true
for other master regulators in different cell types. For example,
only 16% of OCT4 binding sites coincide with the presence of
the active signature in hESC, but those that do show a strong
correlation with genes expressed in hESC, whereas unmarked
OCT4 sites exhibit no such association (Figure S9). These obser-
vations suggest that considering chromatin signaturesmay facil-
itate identification of TF binding events engaged in productive
enhanceosomes and thus relevant for gene expression within
the analyzed cell type. Certainly, TF binding events occurring
outside of the chromatin signatures may also be biologically
meaningful, for example, by priming future enhancer sites (Zaret
and Carroll, 2011) or by functioning in other tissues. Neverthe-
less, decreased sequence conservation at TF sites lacking active
signatures suggests that at least some of these sites may repre-
sent irrelevant binding events (Biggin, 2011).
A Role for Nuclear Receptors NR2F1/2 in NC Gene
Regulation
NR2F1/2 have been implicated in various biological processes
including brain, eye, and vascular development (reviewed in
Lin et al., 2011; Tsai and Tsai, 1997), but their role in the NC
has not been previously examined. Inmousemodels, substantial
redundancy between the two receptors was reported, with many
phenotypes only revealed upon NR2F1/2 double knockdown/
knockout in the relevant cell types (Naka et al., 2008; Tang
et al., 2010). Interestingly, although our expression and genomic
occupancy data are consistent with the potential redundancy
between the two receptors, knockdown of NR2F1 is sufficient
to perturb NC gene expression in hNCC and morphogenesis of
the ectomesenchyme in the frog. In contrast, Nr2f1 knockout
mice undergo relatively unaltered embryogenesis, although
cranial ganglia anomalies (consistent with NC defects) were re-
ported in these animals (Qiu et al., 1997). Distinct requirements
for individual NR2F receptors in different species may be related
to the observation that in hNCC the NR2F2 locus is under direct
control of NR2F1, and thus expression of both receptors is
affected by NR2F1 knockdown. Regardless, our results strongly
suggest that NR2F1 and NR2F2 genes should be systematically
screened for mutations in human craniofacial disorders of
unknown etiology. In support of this notion, individual cases of
patients with a deletion of a single NR2F1 allele or with a micro-
deletion of a larger chromosomal region spanning NR2F2 gene
reported numerous craniofacial abnormalities typically observed
in human neurocristopathies (Brown et al., 2009; Poot et al.,
2007).
Resource for Studies of NC Development and Disease
The enhancer repertoire reported here provides a rich resource
to study NC development. First, many identified regulatory
elements are associated with genes that were previously shownspecifier, TFAP2A, and effectors of ligand-dependent signaling, NR2F1/2,
lishment of transcriptionally permissive enhancer chromatin states and gene
ors of major signaling pathways (e.g., BMP,WNT), are also probably involved in
Stem Cell 11, 633–648, November 2, 2012 ª2012 Elsevier Inc. 645
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but whose regulatory regions were heretofore unknown.
Second, a substantial subset of the identified enhancers is linked
to genes that were not previously implicated in the NC but that
encode signaling regulators, TFs, and cell migration factors.
Thus, our study identified a wealth of new candidates that can
be examined for their role in NC specification and migration.
Third, our work uncovered direct genomic targets of the critical
NC lineage specifier TFAP2A, which can be followed up on
a locus-specific basis. Lastly, enhancer regions reported here
are useful for development of reporter tools for further character-
ization of NCC populations in vitro and in vivo.
It is now well documented that enhancer mutations are linked
to various human pathologies, including neurocristopathies
(Amiel et al., 2010; Sakabe et al., 2012), but their role has not
been systematically examined, largely due to the scarcity of
information on the relevant genomic sequences. Over 500
Mendelian human congenital disorders involve craniofacial mal-
formations with likely NC involvement. Although chromosomal
locations linked to many craniofacial disorders have been iden-
tified, these regions are often large, and disease-associated
mutations outside of the coding sequences are difficult to
pinpoint within broad noncoding territories (Jugessur et al.,
2009). With data sets provided here, hNCC enhancers located
within specific disease-associated chromosomal regions can
be readily detected and their sequences characterized for recur-
rent mutations in patients. Moreover, our work will aid under-
standing of complex multigenic malformations, such as the cleft
lip/palate (Birnbaum et al., 2009; Jugessur et al., 2009), as SNPs
located in proximity of the hNCC enhancers and TF binding sites
could be easily incorporated into genome-wide association
study (GWAS) pipelines.
EXPERIMENTAL PROCEDURES
hNCC Derivation
hESC (H9 line) were differentiated into hNCC as previously described (Bajpai
et al., 2010). Briefly, hESC were incubated with 2 mg/ml collagenase. Once
detached, clusters of 100–200 cells were plated in hNCC differentiation
medium: 1:1 Neurobasal medium/D-MEM F-12 medium (Invitrogen), 0.53
B-27 supplement with Vitamin A (503 stock, Invitrogen), 0.53N-2 supplement
(1003 stock, Invitrogen), 20 ng/ml bFGF (Peprotech), 20 ng/ml EGF (Sigma-Al-
drich), 5 mg /ml bovine insulin (Sigma-Aldrich), and 13Glutamax-I supplement
(1003 stock, Invitrogen). Medium was changed every other day. After
6–7 days of differentiation, resultant neuroepithelial spheres attached and
gave rise to migratory hNCC. Three to four days after the appearance of the
first hNCC, cells were harvested for subsequent experiments.
ChIP, Sequential ChIP, FAIRE, and Antibodies
Chromatin immunoprecipitation (ChIP) and FAIRE assays were performed
from approximately 107 hNCC cells per experiment (Rada-Iglesias et al.,
2011). Sequential ChIPs were performed as previously described with slight
modifications (Furlan-Magaril et al., 2009). All antibodies used in this study
have been previously reported as suitable for ChIP and/or ChIP-seq: p300
(sc-585, Santa Cruz Biotechnology), H3K4me1 (ab8895, Abcam), H3K27ac
(ab4729, Abcam), H3K4me3 (39159, Active Motif), H3K27me3 (39536,
Active Motif), NR2F1 (PP-H8132-00, Perseus Proteomics), NR2F2 (PP-
H7147-00, Perseus Proteomics), and TFAP2A (sc-184, Santa Cruz
Biotechnology).
ChIP-seq
DNA libraries were prepared from hNCC p300 ChIP, hNCC FAIRE, hNCC
H3K4me3 ChIP, hNCC H3K4me1 ChIP, hNCC H3K27me3 ChIP, hNCC646 Cell Stem Cell 11, 633–648, November 2, 2012 ª2012 Elsevier InH3K27ac ChIP, hNCC NR2F1 ChIP, hNCC NR2F2 ChIP, hNCC TFAP2A
ChIP, hNCC input DNA, St11-14 Chicken H3K27ac ChIP, St20 Chicken
H3K27ac ChIP, St11-14 Chicken input DNA, St20 Chicken input DNA. ChIP-
seq, and FAIRE-seq and input libraries were prepared according to Illumina
protocol and sequenced using Illumina Genome Analyzer. All sequences
were mapped by ELAND software (Illumina) and analyzed by QuEST 2.4 soft-
ware (Valouev et al., 2008). Aforementioned human and chicken ChIP-seq data
sets have been deposited into GEO repository under accession numbers
GSE28876 and GSE38066, respectively. Histone modification and p300
ChIP-seq data sets from hESC and hNEC have been previously reported
and deposited into GEO database (accession number GSE24447) (Rada-Igle-
sias et al., 2011).
Enhancer Classification
Distal p300 enriched elements were defined as those that were not enriched in
H3K4me3. Subsequently, those distal p300 elements in hESC, hNEC, or hNCC
were classified in the following groups (Data S1):
d Active enhancers: distal p300 regions located within 2 Kb of regions en-
riched in H3K4me1 and H3K27ac.
d Poised enhancers: distal p300 regions located within 2 Kb of regions en-
riched in H3K27me3 and more than 2 Kb away from regions enriched in
H3K27ac.
In addition, when comparing the binding profiles of transcription factors
(NR2F1/2, TFAP2A) with the location of hNCC enhancers, we considered
two additional categories.
d Partial active enhancers: distal transcription factor bound regions that
overlapped p300-bound regions not corresponding to active enhancers
or distal regions not enriched in p300 but enriched in H3K4me1 and
H3K27ac.
d Unmarked: distal transcription factor bound regions located more than
2 Kb away from regions enriched in p300, H3K27ac, H3K4me1, or
H3K27me3.shRNA-Mediated NR2F1 Knockdown
shRNA against NR2F1 was purchased from Open biosystems (sequence:
CGCCCACCCAGCAGAAATACAATAGTGAAGCCACAGATGTATTGTATTTCT
GCTGGGTGGGCTT, Oligo ID: V2LHS_239287). The NR2F1 shRNA-encoding
sequence was cloned in the pTRIPZ vector, in which shRNA expression is
doxycycline inducible. pTRIPZ vectors expressing either NR2F1 shRNA or
control-scrambled shRNA were used to transduce hESC. Infected hESC
were then expanded in media containing puromycin (1 mg/ml) for at least two
passages. hESC were then differentiated into hNCC, having both puromycin
(1 mg/ml) and doxycycline (1 mg/ml) in the correspondingmedia. Three days after
the appearance of the first hNCC, total RNA was isolated and cDNA generated
as described above. RT-qPCR analysis of gene expression was performed
using two independent biological replicates for both NR2F1 and control
shRNA expressing cells and performing each qPCR reaction in triplicate.
Fold changes in gene expression were calculated using the delta-delta Ct
method and the EEF2 gene as a loading control. For all genes, expression is
normalized to that of the housekeeping gene EEF2 and presented relative to
hNCC expressing control-scrambled shRNA.
In Vitro Enhancer Reporter Assays
Representative active hNCC enhancers bound byNR2F1/2 andwith a uniquely
strong match to the NR2F1/2 binding motif were selected. Wild-type enhancer
sequences or enhancer sequences with deleted NR2F1/2 binding motif (Data
S5) were cloned into a lentiviral vector (Sin-minTK-eGFP) in front of a minimal
TK promoter driving GFP expression. hESC were transduced with the corre-
sponding lentiviruses and subsequently expanded for at least two passages
in Neomycin (0.2 mg/ml) containing media. Infected hESC were then differen-
tiated into hNCC and GFP fluorescence levels were monitored. For quantifica-
tion of the reporter assays, hNCCs were separated into single cell suspension
by trypsin treatment. Cell GFP fluorescence was analyzed on CS&T calibrated
BD FACS Aria II SORP flow cytometer on 488 nm laser line. Percent of GFP
positive cells were determined by histogram interval gate set on GFP negativec.
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population.ACCESSION NUMBERS
Human and chicken ChIP-seq data sets have been deposited into GEO repos-
itory under accession numbers GSE28876 and GSE38066, respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes nine figures, one table, five data sets, and
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